Rakuten Medical, Inc. is a global biotechnology company focused on developing precision, cell-targeting investigational therapies utilizing its Alluminox™ technology platform. The company is dedicated to conquering cancer and aims to create a society where cancer patients can lead fulfilling lives. Its first clinical product, ASP-1929 PIT, has received marketing approval in Japan for treating unresectable locally advanced or recurrent head and neck cancer and is currently undergoing Phase III clinical testing globally. Headquartered in the United States, Rakuten Medical operates in multiple countries, including Japan, Taiwan, Switzerland, and India, and is committed to advancing novel anticancer therapies into registration trials and commercialization.